

# Key Figures (IFRS)

MorphoSys Group (in million €, if not stated otherwise)

	12/31/15	12/31/14	12/31/13	12/31/12	12/31/11	12/31/10	12/31/09	12/31/08	12/31/07	12/31/06
<b>RESULTS<sup>1</sup></b>										
Revenues	106.2	64.0	78.0	51.9	82.1	87.0	81.0	71.6	62.0	53.0
Cost of Goods Sold	0.0	0.0	0.0	0.0	0.0	7.3	6.7	7.1	7.9	8.0
R&D Expenses	78.7	56.0	49.2	37.7	55.9	46.9	39.0	27.6	22.2	17.5
SG&A Expenses	15.1	14.1	18.8	12.1	14.9	23.2	23.9	20.5	24.8	21.4
Personnel Expenses (Excluding Stock-Based Compensation)	32.4	26.7	27.4	24.1	27.7	29.6	26.1	21.5	18.8	18.1
Capital Expenditure	8.8	20.5	5.6	1.8	2.9	13.8	3.8	3.8	12.0	4.0
Depreciation of Tangible Assets	1.5	1.4	1.5	1.7	1.7	2.1	1.6	1.5	1.5	1.5
Amortization of Intangible Assets	1.9	2.7	3.3	3.5	3.8	4.0	3.8	4.8	3.7	3.4
EBIT	17.2	(5.9)	9.9	2.5	9.8	13.1	12.8	16.5	8.3	5.4
Net Profit/(Loss)	14.9	(3.0)	13.3	1.9	8.2	9.2	9.0	13.2	11.5	6.0
Net Profit/(Loss) from Discontinued Operations	-	-	6.0	(0.4)	0.0	-	-	-	-	-
<b>BALANCE SHEET</b>										
Total Assets	400.1	426.5	447.7	224.3	228.4	209.8	206.1	203.3	184.7	127.8
Cash, Marketable Securities and Other Financial Assets	298.4	352.8	390.7	135.7	134.4	108.4	135.1	137.9	106.9	66.0
Intangible Assets	79.6	46.0	35.1	35.0	66.0	69.2	17.4	19.7	22.3	14.8
Total Liabilities	37.3	77.7	95.5	22.3	31.3	23.9	32.2	41.3	39.2	27.8
Stockholders' Equity	362.7	348.8	352.1	202.0	197.1	185.9	173.9	162.0	145.5	100.1
Equity Ratio (in %)	91%	82%	79%	90%	86%	89%	84%	80%	79%	78%
<b>MORPHOSYS SHARE</b>										
Number of Shares Issued	26,537,682	26,456,834	26,220,882	23,358,228	23,112,167	22,890,252	22,660,557	22,478,787	22,160,259	20,145,966
Group Earnings/(Loss) per Share, Diluted (in €)	0.57	(0.12)	0.54	0.08	0.36	0.4	0.4	0.59	0.53	0.31
Dividend (in €)	-	-	-	-	-	-	-	-	-	-
Share Price (in €)	57.65	76.63	55.85	29.3	17.53	18.53	17.04	18.75	16.1	18.12
<b>PERSONNEL DATA</b>										
Total Group Employees (Number <sup>2</sup> )	365	329	299	421	446	464	404	334	295	279

<sup>1</sup> Due to the agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the AbD Serotec segment, for the years 2013, 2012 and 2011, revenues, income and expenses in connection with the transaction are shown in the line item "Net Profit/(Loss) from Discontinued Operations." All other line items consist of amounts from continuing operations.

<sup>2</sup> 2005 to 2012 including employees from the discontinued operations of AbD Serotec.